Coronary artery disease| Volume 111, ISSUE 10, P1394-1400, May 15, 2013

Download started.


Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]

      A first pilot study of interleukin-1 blockade in ST-segment elevation acute myocardial infarction showed improved remodeling. In the present second pilot study, we enrolled 30 patients with clinically stable ST-segment elevation acute myocardial infarction randomized to anakinra, recombinant interleukin-1 receptor antagonist, 100 mg/day for 14 days or placebo in a double-blind fashion. The primary end point was the difference in the interval change in left ventricular (LV) end-systolic volume index between the 2 groups within 10 to 14 weeks. The secondary end points included changes in the LV end-diastolic volume index, LV ejection fraction, and C-reactive protein levels. No significant changes in end-systolic volume index, LV end-diastolic volume index, or LV ejection fraction were seen in the placebo group. Compared to placebo, treatment with anakinra led to no measurable differences in these parameters. Anakinra significantly blunted the increase in C-reactive protein between admission and 72 hours (+0.8 mg/dl, interquartile range −6.4 to +4.2, vs +21.1 mg/dl, interquartile range +8.7 to +36.6, p = 0.002), which correlated with the changes in LV end-diastolic volume index and LV end-systolic volume index at 10 to 14 weeks (R = +0.83, p = 0.002, and R = +0.55, p = 0.077, respectively). One patient in the placebo group (7%) died. One patient (7%) in the anakinra group developed recurrent acute myocardial infarction. More patients were diagnosed with new-onset heart failure in the placebo group (4, 27%) than in the anakinra group (1, 7%; p = 0.13). When the data were pooled with those from the first Virginia Commonwealth University-Anakinra Remodeling Trial (n = 40), this difference reached statistical significance (30% vs 5%, p = 0.035). In conclusion, interleukin-1 blockade with anakinra blunted the acute inflammatory response associated with ST-segment elevation acute myocardial infarction. Although it failed to show a statistically significant effect on LV end-systolic volume index, LV end-diastolic volume index, or LV ejection fraction in this cohort of clinically stable patients with near-normal LV dimensions and function, anakinra led to a numerically lower incidence of heart failure.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Frangogiannis N.G.
        Regulation of the inflammatory response in cardiac repair.
        Circ Res. 2012; 110: 159-173
        • Mezzaroma E.
        • Toldo S.
        • Farkas D.
        • Seropian I.M.
        • Van Tassell B.W.
        • Salloum F.N.
        • Kannan H.R.
        • Menna A.C.
        • Voelkel N.F.
        • Abbate A.
        The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse.
        Proc Natl Acad Sci U S A. 2011; 108: 19725-19730
        • Dinarello C.A.
        Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
        Blood. 2011; 117: 3720-3732
        • Dinarello C.A.
        • Simon A.
        • van der Meer J.W.
        Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
        Nat Rev Drug Discov. 2012; 11: 633-652
        • Abbate A.
        • Van Tassell B.W.
        • Biondi-Zoccai G.G.
        Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.
        BioDrugs. 2012; 26: 217-233
        • Abbate A.
        • Salloum F.
        • Vecile E.
        • Das A.
        • Hoke N.
        • Straino S.
        • Biondi-Zoccai G.G.L.
        • Houser J.
        • Qureshi I.
        • Ownby E.
        • Gustini E.
        • Biasucci L.
        • Severino A.
        • Capogrossi M.
        • Vetrovec G.
        • Crea F.
        • Baldi A.
        • Kukreja R.
        • Dobrina A.
        Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.
        Circulation. 2008; 117: 2670-2683
        • Van Tassell B.W.
        • Varma A.
        • Salloum F.N.
        • Das A.
        • Seropian I.M.
        • Toldo S.
        • Smithson L.
        • Hoke N.N.
        • Chau V.Q.
        • Robati R.
        • Abbate A.
        Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice.
        J Cardiovasc Pharmacol. 2010; 55: 117-122
        • Abbate A.
        • Van Tassell B.W.
        • Seropian I.M.
        • Toldo S.
        • Robati R.
        • Varma A.
        • Salloum F.N.
        • Smithson L.
        • Dinarello C.A.
        Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse.
        Eur J Heart Fail. 2010; 12: 319-322
        • Abbate A.
        • Kontos M.C.
        • Grizzard J.D.
        • Biondi-Zoccai G.G.
        • Van Tassell B.W.
        • Robati R.
        • Roach L.M.
        • Arena R.A.
        • Roberts C.S.
        • Varma A.
        • Gelwix C.C.
        • Salloum F.N.
        • Hastillo A.
        • Dinarello C.A.
        • Vetrovec G.W.
        • VCU-ART Investigators
        Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] pilot study).
        Am J Cardiol. 2010; 105: 1371-1377
        • Saraste A.
        • Nekolla S.
        • Schwaiger M.
        Contrast-enhanced magnetic resonance imaging in the assessment of myocardial infarction and viability.
        J Nucl Cardiol. 2008; 15: 105-117
        • Orn S.
        • Manhenke C.
        • Ueland T.
        • Dams J.
        • Mollnes T.
        • Edvardsen T.
        • Aukrust P.
        • Dickstein K.
        C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction.
        Eur Heart J. 2009; 30: 1180-1186
        • Théroux P.
        • Armstrong P.W.
        • Mahaffey K.W.
        • Hochman J.S.
        • Malloy K.J.
        • Rollins S.
        • Nicolau J.C.
        • Lavoie J.
        • Luong T.M.
        • Burchenal J.
        • Granger C.B.
        Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
        Eur Heart J. 2005; 26: 1964-1970
        • Morrow D.A.
        • Antman E.M.
        • Charlesworth A.
        • Cairns R.
        • Murphy S.A.
        • de Lemos J.A.
        • Giugliano R.P.
        • McCabe C.H.
        • Braunwald E.
        TIMI risk score for ST-elevation myocardial infarction: a convenient bedside, clinical score for risk assessment at presentation.
        Circulation. 2000; 102: 2031-2037
        • Pearson T.A.
        • Mensah G.A.
        • Alexander R.W.
        • Anderson J.L.
        • Cannon III, R.O.
        • Criqui M.
        • Fadl Y.Y.
        • Fortmann S.P.
        • Hong Y.
        • Myers G.L.
        • Rifai N.
        • Smith Jr., S.C.
        • Taubert K.
        • Tracy R.P.
        • Vinicor F.
        • Centers for Disease Control and Prevention
        • American Heart Association
        Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
        Circulation. 2003; 107: 499-511
        • Biasucci L.M.
        • Liuzzo G.
        • Grillo R.L.
        • Caligiuri G.
        • Rebuzzi A.G.
        • Buffon A.
        • Summaria F.
        • Ginnetti F.
        • Fadda G.
        • Maseri A.
        Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.
        Circulation. 1999; 99: 855-860
        • CAPRICORN Investigators
        Effects of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial.
        Lancet. 2001; 357: 1385-1390
        • Doughty R.N.
        • Whalley G.A.
        • Walsh H.A.
        • Gamble G.D.
        • López-Sendón J.
        • Sharpe N.
        • CAPRICORN Echo Substudy Investigators
        Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy.
        Circulation. 2004; 109: 201-206
        • Pitt B.
        • Remme W.
        • Zannad F.
        • Neaton J.
        • Martinez F.
        • Roniker B.
        • Bittman R.
        • Hurley S.
        • Kleiman J.
        • Gatlin M.
        • Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Weir R.A.
        • Mark P.B.
        • Petrie C.J.
        • Clements S.
        • Steedman T.
        • Ford I.
        • Ng L.L.
        • Squire I.B.
        • Wagner G.S.
        • McMurray J.J.
        • Dargie H.J.
        Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?.
        Am Heart J. 2009; 157: 1088-1096
        • Furst D.
        Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
        Clin Ther. 2004; 26: 1960-1975